Programme

Room N101B
2024-08-10
09:00-10:30
AASLD-HKASLD Joint Symposium (1): Hepatitis B
09:00
Indeterminate Phase of Chronic Hepatitis B – What Is It and Does It Matter?
09:25
New Pharmacological Treatments for Chronic Hepatitis B
09:50
The Impact of New Guidelines on Managing Hepatitis B
10:15
Q & A
Room N101B
2024-08-10
11:00-12:30
Viral Hepatitis
11:00
Novel HBV and HCV Viral Markers for Diagnosis and On-Treatment Monitoring
11:25
Navigating The Various Realms of Hepatitis B With The Latest Treatment
11:50
Assessing and Managing DDIs in HCV Treatment: Lessons from Clinical Practice
12:15
Q & A
Room N101B
2024-08-10
15:50-17:20
New Development in Hepatology
15:50
What Can We Learn from Auto-Brewery Syndrome
16:15
Management of Critically Ill Patients with Cirrhosis
16:40
Portal Hypertension: What’S New in 2024?
17:05
Q & A
Room N101B
2024-08-10
17:20-18:20
Towards Functional Cure of HBV
17:20
What Are The Best Combination Regimens to Achieve Functional Cure of HBV
17:45
The Role of MTCT of HBV in Hepatitis Elimination
18:10
Q & A
Room N101B
2024-08-11
09:00-10:30
AASLD-HKASLD Joint Symposium (2): Advanced Liver Disease
09:00
New Insights in the Pathogenesis of HCC
09:20
Management of Patients in The Baveno VII Gray Zone
09:40
Role of Gut Microbiota in Advanced Liver Disease
10:00
Use of Vasoactive Drugs and Albumin in Cirrhosis
10:20
Q & A
Room N101B
2024-08-11
11:00-12:30
General Hepatology Update
11:00
Lean MAFLD
11:25
HCC Risk Prediction – Is There Room for Improvement?
11:50
Micro-elimination of HCV in Hong Kong
12:15
Q & A
AASLD-HKASLD Joint Symposium (1): Hepatitis B
Room N101B
2024-08-10
09:00
09:00
Indeterminate Phase of Chronic Hepatitis B – What Is It and Does It Matter?
09:25
New Pharmacological Treatments for Chronic Hepatitis B
09:50
The Impact of New Guidelines on Managing Hepatitis B
10:15
Q & A
Viral Hepatitis
Room N101B
2024-08-10
11:00
11:00
Novel HBV and HCV Viral Markers for Diagnosis and On-Treatment Monitoring
11:25
Navigating The Various Realms of Hepatitis B With The Latest Treatment
11:50
Assessing and Managing DDIs in HCV Treatment: Lessons from Clinical Practice
12:15
Q & A
New Development in Hepatology
Room N101B
2024-08-10
15:50
15:50
What Can We Learn from Auto-Brewery Syndrome
16:15
Management of Critically Ill Patients with Cirrhosis
16:40
Portal Hypertension: What’S New in 2024?
17:05
Q & A
Towards Functional Cure of HBV
Room N101B
2024-08-10
17:20
17:20
What Are The Best Combination Regimens to Achieve Functional Cure of HBV
17:45
The Role of MTCT of HBV in Hepatitis Elimination
18:10
Q & A
AASLD-HKASLD Joint Symposium (2): Advanced Liver Disease
Room N101B
2024-08-11
09:00
09:00
New Insights in the Pathogenesis of HCC
09:20
Management of Patients in The Baveno VII Gray Zone
09:40
Role of Gut Microbiota in Advanced Liver Disease
10:00
Use of Vasoactive Drugs and Albumin in Cirrhosis
10:20
Q & A
General Hepatology Update
Room N101B
2024-08-11
11:00
11:00
Lean MAFLD
11:25
HCC Risk Prediction – Is There Room for Improvement?
11:50
Micro-elimination of HCV in Hong Kong
12:15
Q & A